Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07538570 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Pain Treatment After Total Knee Arthroplasty

A Phase 4 study, sponsored by Vertex Pharmaceuticals Incorporated.

Recruiting
Registry status
Phase 4
Development phase
60
Enrollment target

NCT07538570: Recruiting Phase 4 study, sponsored by Vertex Pharmaceuticals Incorporated.

NCT07538570 is a Phase 4 study that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 60 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07538570, a Phase 4 study, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.

RECRUITING
Registry status
Phase 4
Development phase
60 participants
Enrollment target

Study Summary

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Interventions

  • DRUG Placebo
  • DRUG Suzetrigine

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-04-24
Est. Completion 2027-01-30
Phase Phase 4
Vertex Pharmaceuticals Incorporated

191 total trials

What NCT07538570 shows while recruiting

NCT07538570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07538570 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07538570 about?

NCT07538570 is a clinical study titled "Evaluation of Pain Treatment After Total Knee Arthroplasty". The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

What is the current status of trial NCT07538570?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-04-24. Estimated completion is 2027-01-30.

What interventions are being tested in trial NCT07538570?

The interventions under investigation include: Placebo (DRUG), Suzetrigine (DRUG).

Who is sponsoring clinical trial NCT07538570?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07538570's enrollment target sits among peer trials

60 1125th of 2000 higher than 799 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07538570, the US trial registry maintained by the National Library of Medicine. NCT07538570 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.